Expertise in
10
conditions

Barbara F. Eichhorst

Kerpener Str. 62, 
Koeln, NW, DE 
Expertise in
10
conditions
Kerpener Str. 62, 
Koeln, NW, DE 

Overview

Barbara Eichhorst practices practicing medicine in Koeln, Germany.

Ms. Eichhorst is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Leukemia.

She is actively involved in clinical research, co-authoring 192 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Enrollment Status: Completed
Publish Date: December 30, 2024
Intervention Type: Drug, Biological
Study Drugs: Fludarabine, Cyclophosphamide, Rituximab, Ibrutinib, Bendamustine, Venetoclax, Obinutuzumab, Ibrutinib
Study Phase: Phase 3

192 Total Publications

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2026

Frequently Asked Questions about Barbara F. Eichhorst

Is Barbara F. Eichhorst a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Barbara F. Eichhorst is classified as an Elite expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Barbara F. Eichhorst participate in research or clinical trials?

Yes. Barbara F. Eichhorst has published 192 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Barbara F. Eichhorst's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Eichhorst's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile